MesotheliomaPhase 1NCT06885697
TNhYP218 CAR T Cells
Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma
25 Phase 1 studies recruiting right now, most recently updated first.
Open the Phase 2 page · a list of only those studies
Triangle is made by Triangle Health, Inc.
Lung and thoracic25 studies
MesotheliomaPhase 1NCT06885697
Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma
Early-Stage Resectable Non-Small Cell Lung CancerPhase 1NCT06566443Papers
Honokiol in Early-Stage Resectable Non-Small Cell Lung Cancer
Resectable Pleural MesotheliomaPhase 1/2NCT05932199
Neoadjuvant Durvalumab and Tremelimumab With and Without Chemotherapy for Mesothelioma
MTAP-Deleted Advanced Non-Small Cell Lung CancerPhase 1/2NCT07579221
Ph1/2 Trial Of Navlimetostat With Pumitamig In MTAP-Deficient Advanced Non-Small Cell Lung Cancer
MET Exon 14 Skipping Non-Small Cell Lung CancerPhase 1NCT07619339
Tepotinib and Ivonescimab in People With Non-Small Cell Lung Cancer
Non Small Cell Lung CancerPhase 1NCT05681780Papers
CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLC
Leptomeningeal Disease From Melanoma or NSCLCPhase 1NCT07814352
SX-682 in Combination With Proton Craniospinal Irradiation (pCSI) in People With Leptomeningeal Disease
Extensive-Stage SCLC, Brain Metastases, Soft Tissue Sarcoma and Head and Neck CancerPhase 1NCT07139990
Personalized Radiotherapy for Individualized Treatment Strategies and Monitoring (PRISM)
Extensive-stage Small-cell Lung CancerPhase 1NCT06807632Papers
Valemetostat in Combination With Atezolizumab in People With Lung Cancer
Malignant Pleural EffusionPhase 1NCT07192900
Fast TILs to Treat Metastatic Cancer Patients With Pleural Disease
NSCLC Stage IVPhase 1/2NCT05950139
Peptide Vaccine To Prevent Acquired Resistance In Patients With Advanced ALK+ NSCLC
Non-Small Cell Lung CancerPhase 1/2NCT06088771
Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC
Untreated Stage IV or Recurrent Non-Small Cell Lung CancerPhase 1/2NCT07355205
First-Line Ipilimumab Plus Nivolumab and Nogapendekin Alfa Inbakicept (N-803) in Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer
Locally Advanced Lung Non-Small Cell CarcinomaPhase 1NCT05136846
Papaverine in Combination With Chemoradiation for the Treatment of Stage II-III Non-small Cell Lung Cancer
Lung Non-Small Cell CarcinomaPhase 1NCT06225427Papers
Gilteritinib for the Treatment of ALK NSCLC
Locally Advanced or Metastatic Non-Small Cell Lung Cancer (ECOG 2)Phase 1NCT04297605
Pembrolizumab and Single Agent Chemotherapy as First Line Treatment for Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer With Eastern Cooperative Oncology Group (ECOG) Performance Status of 2
Relapsed/Refractory Small Cell Lung CancerPhase 1NCT07249879
This Study is an Open-lable, Early Study to Evaluate the Safety, Feasibility, Cytokinetics, and Preliminary Efficacy of GC511B in DLL3+ Relapsed/Refractory Small Cell Lung Cancer
Non-Small Cell Lung Cancer With Brain MetastasesPhase 1/2NCT07535463
Ivonescimab, Chemotherapy, and Stereotactic Radiosurgery for People With Non-Small Cell Lung Cancer
ALK-Positive Lung Cancer With Brain MetastasesPhase 1/2NCT05987644
Delayed or Upfront Brain RAdiotherapy in Treatment naïve Lung Cancer Patients With Asymptomatic or Minimally Symptomatic Brain Metastases and ALK rEarrangements
Malignant Pleural EffusionPhase 1NCT07443020
Fast TILs to Treat Metastatic Pleural Effusions From Epithelial or Mesothelial Primary Tumors
Advanced EGFR-Mutant Non-Small Cell Lung CancerPhase 1NCT04762199
MRX-2843 and Osimertinib for the Treatment of Advanced EGFR Mutant Non-small Cell Lung Cancer
Metastatic Non-Small Cell Lung CancerPhase 1NCT05452005
Fluorine-18-AlphaVBeta6-Binding Peptide Positron Emission Tomography in Metastatic Non-Small Cell Lung Cancer
Metastatic Lung Non-Small Cell CarcinomaPhase 1NCT05234307
PBF-1129 and Nivolumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer
Advanced KRAS G12C-Mutant Non-Small Cell Lung CancerPhase 1NCT05815173
Ladarixin With Sotorasib in Advanced NSCLC